1) AMPE puts out a BS press release on it's meeting with FDA on Optina. " planning the design of the next trial, which we are going to discuss with the FDA at the end of July 2012 to clarify the path for approval for Optina™.""
2) AEGIS capital ("Aegis Capital Corp. and Fordham Financial Management, Inc. acted as joint book-running managers for the offering"), iniaites coverage with a BUY rating.
3) Richard Cavalli puts another blog post on Seeking Alpha or Motley fool about what a good stock this is.
Wow, you're a genius. I predicted all the short bashing articles after the pumps too and I predict that there are more to come. However, I trust real analysts with real coverage initiations for real companies by real companies that are experts in their field. You knew this was coming, it was long overdue. Now let the truth be told and buy while you still can. This company is here to stay and sooner or later you and I will be using their drugs. I'd invest on that!